Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in southern Israel: Implication for immunizing with conjugate vaccines

Journal of Infectious Diseases

Volumn 181, Issue 4, 2000, Pages 1322-1329

  Dagan, Ron ^a   Givon Lavi, Noga ^a   Shkolnik, Liana ^a   Yagupsky, Pablo ^a   Fraser, Drora ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFICACY; HUMAN; IMMUNIZATION; ISRAEL; MAJOR CLINICAL STUDY; NONHUMAN; OTITIS MEDIA; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ACUTE DISEASE; ARABS; BACTERIAL VACCINES; CHILD, PRESCHOOL; HUMANS; INFANT; ISRAEL; JUDAISM; MENINGOCOCCAL VACCINES; OTITIS MEDIA; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 0034022066     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315383     Document Type: Article

References (55)

1. 1. Teele DW, Klein JO, Rosner B, et al. Middle ear disease and the practice of pediatrics: burden during the first five years of life. JAMA 1983;249: 1026-9.
2. 2. Gates GA. Cost-effectiveness considerations in otitis media treatment. Otolaryngol Head Neck Surg 1996;14:525-30.
3. 3. Klein JO. Microbiologic efficacy of antibacterial drugs for acute otitis media. Pediatr Infect Dis J 1993;12:973-5.
4. 4. Teele DW, Klein JO, Rosner B, et al. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective cohort study. J Infect Dis 1989;160:83-94.
5. 5. Marchant CD, Shurin PA, Turczyk VA, et al. Course and outcome of otitis media in early infancy: a prospective study. J Pediatr 1984;104:826-31.
6. 6. Del Beecaro MA, Mendelman PM, Inglis AF, et al. Bacteriology of acute otitis media: a new perspective. J Pediatr 1992;120:81-4.
7. 7. Klein JO. Otitis media. Clin Infect Dis 1994;19:823-33.
8. 8. Howie VM, Ploussard JH. Efficacy of fixed combination antibiotics versus separate components in otitis media. Clin Pediatr 1972;11:205-14.
9. 9. Dagan R. Can the choice of antibiotics for therapy of acute otitis media be logical? Eur J Clin Microbiol Infect Dis 1998;17:1-5.
10. 10. Dagan R, Abramson O, Leibovitz E, et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis J 1996;15:980-5.
11. 11. Gehanno P, Lenoir G, Berche P. In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media. Antimicrob Agents Chemother 1995;399:271-2.
12. 12. Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic efficacy of a three-day intramuscular ceftriaxone regimen in nonresponsive acute otitis media. Pediatr Infect Dis J 1998;17:1126-31.
13. 13. Munford RS, Murphy TV. Antimicrobial resistance in Streptococcus pneumoniae: can immunization prevent its spread? J Investig Med 1994;42: 613-21.
14. 14. Salazar JC, Daly KA, Giebink GS, et al. Low cord blood pneumococcal immunoglobulin G (IgG) antibodies predict early onset acute otitis media in infancy. Am J Epidemiol 1997;145:1048-56.
15. 15. Shurin PA, Rehmus JM, Johnson CE, et al. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children. J Pediatr 1993;123:801-10.
16. 16. Karma P, Pukander J, Sipila M. Prevention of otitis media in children by pneumococcal vaccination. Otolaryngology 1985;6:173-84.
17. 17. Mäkela PH, Leinonen M, Pukander J, Karma P. A study of the pneumococcal vaccine in prevention of clinically acute attacks of recurrent otitis media. Rev Infect Dis 1981;3(Suppl):S124-32.
18. 18. Teele DW, Klein JO. Use of pneumococcal vaccine for prevention of recurrent acute otitis media in infants in Boston. Rev Infect Dis 1981;3(Suppl): S113-8.
19. 19. Howie VM, Ploussard J, Sloyer JL, Hill JC. Use of pneumococcal polysaccharide vaccine in preventing otitis media in infants: different results between racial groups. Pediatrics 1984;73:79-81.
20. 20. Giebink GS, Koskela M, Vella PP, et al. Pneumococcal capsular polysaccharide meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J Infect Dis 1993;167:347-55.
21. 21. Klein DL. Pneumococcal conjugate vaccines: review and update. Microb Drug Resist 1995;1:49-58.
22. 22. Eskola J, Anttila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J 1999;18:543-51.
23. 23. Sniadack DH, Schwartz B, Lipman H, et al. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children - implications for vaccine strategies. Pediatr Infect Dis J 1995;14:503-10.
24. 24. Dagan R, Yagupsky P, Goldbart A, Wasas A, Klugman K. Increasing prevalence of penicillin-resistant pneumococcal infections in children in southern Israel: implications for future immunization policies. Pediatr Infect Dis J 1994;13:782-6.
25. 25. Breiman R, Butler J, Tenover F, Elliott J, Facklam R. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271: 1831-5.
26. 26. Haglund LA, Istre GR, Pickett DA, Welch DF. Fine DP, Pneumococcus Study Group. Invasive pneumococcal disease in central Oklahoma: emergence of high-level penicillin resistance and multiple antibiotic resistance. J Infect Dis 1993;168:1532-6.
27. 27. Welby P, Keller P, Cromien J, Tebas P, Storch G. Resistance to penicillin and non-beta-lactam antibiotics of Streptococcus pneumoniae at a children's hospital. Pediatr Infect Dis J 1994;13:281-7.
28. 28. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174:1271-8.
29. 29. Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997;16:1060-4.
30. 30. Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination [letter]. Lancet 1996;348:271-2.
31. 31. Mbelle N, Wasas A, Huebner R, Kimura A, Chang I, Kimura A. Immunogenicity and impact on carriage of 9-valent pneumococcal conjugate given to infants in Soweto, South Africa [abstract LB21]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:13.
32. 197 on nasopharyngeal carriage of vaccine type and non vaccine type S. pneumoniae strains among day-care center attendees [abstract G-52]. In: Program and abstract of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998:299.
33. 33. Black S, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: results of the northern California Kaiser Permanente efficacy trial [abstract LB9]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998:23.
34. 34. Black S, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: impact on pneumonia, otilis media, and an update on invasive disease - results of the Northern California Kaiser Permanente efficacy trial [abstract 1398]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999:379.
35. 35. Eskola J, Kilpi T. Efficacy of a heptavalent pneumococcal conjugate vaccine (PncCRM) against serotype-specific, culture-confirmed pneumococcal acute otitis media (AOM) in infants and children [abstract LB-13]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco) (addendum). Washington, DC: American Society for Microbiology, 1999:16.
36. 36. Dagan R, Sofer S, Klish WJ, et al. Growth and nutritional status of Bedouin infants in the Negev desert, Israel: evidence for marked stunting in the presence of only mild malnutrition. Am J Clin Nutr 1983;38:747-56.
37. 37. Levy A, Fraser D, Vardi H, Dagan R. Hospitalizations for infectious diseases in Jewish and Bedouin children in southern Israel: reflection of population differences in disease burden. Eur J Epidemiol 1998;14:179-86.
38. 38. Dagan R, Landau D, Haikin H, Tal A. Hospitalization of Jewish and Bedouin infants in Southern Israel for bronchiolitis caused by respiratory syncytial virus. Pediatr Infect Dis J 1993;12:381-6.
39. 39. Austrian R. The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med 1976;43:669-703.
40. 40. Jacobs MR, Basaksouzian S. Appelbaum PC, Bolstrom A. Evaluation of the E-test for susceptibility testing of pneumococci. Diagn Microbiol Infect Dis 1992;15:473-8.
41. 41. Dagan R, Piglansky L. Yagupsky P, Fliss DM, Leiberman A, Leibovitz E. Bacteriologic response in acute otitis media: comparison between azithromycin, cefaclor and amoxicillin [abstract K103]. In: Program and abstract of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:346.
42. 42. Faden H, Duffy L, Boeve M. Otitis media: back to basics. Pediatr Infect Dis J 1998;17:1105-13.
43. 43. Rodriguez WJ, Schwartz RH. Streptococcus pneumoniae causes otitis media with higher fever and more redness of tympanic membranes than Haemophilus influenzae or Moraxella catarrhalis. Pediatr Infect Dis J 1999; 18:942-4.
44. 44. Yagupsky P, Porat N, Fraser D, et al. Acquisition, carriage, and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day care facility in southern Israel. J Infect Dis 1998;177: 1003-12.
45. 45. De Lencastre H, Kristinsson KG, Brito-Avo A, et al. Carriage of respiratory tract pathogens and molecular epidemiology of Streptococcus pneumoniae colonization in healthy children attending day care centers in Lisbon, Portugal. Microb Drug Resist 1999;5:19-29.
46. 46. Givon N, Dagan R, Fraser D, Yagupsky P, Porat N. Marked differences in pneumococcal carriage and resistance patterns between day care centers located within a small area. Clin Infect Dis 1999;29:1276-80.
47. 47. Syrogiannopoulos GA, Grivea IN, Beratis NG, et al. Resistance patterns of Streptococcus pneumoniae from carriers attending day-care centers in southwestern Greece. Clin Infect Dis 1997;25:188-94.
48. 48. Kellner JD, Ford-Jones L, Toronto Child Centre Study Group. Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers. Arch Pediatr Adolesc Med 1999;153:495-502.
49. 49. Cohen R, Levy C, Boucherat M, Langue J, De la Roeque F. Characteristics and outcome of acute otitis media according to day attendance [abstract O-24]. In: Abstracts of the 17th annual meeting of the European Society for Paediatric Infectious Diseases (Crete). European Society for Paediatric Infectious Diseases, 1999:34.
50. 50. Dagan R, Melamed R, Muallem M, Piglansky L, Yagupsky P. Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first two years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. J Infect Dis 1996;174:1352-5.
51. 51. Leach AJ, Boswell JB, Asche V, Nienhuys TG, Mathews JD. Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian Aboriginal infants. Pediatr Infect Dis J 1994; 13:983-9.
52. 52. Faden H, Duffy L, Wasielewski R, et al. Relationship between nasopharyngeal colonization and the development of otitis media in children. J Infect Dis 1997;175:1440-5.
53. 53. Aaberge IS, Lovik M, Hoogerhout P, Poolman J, Pawlowski A, Svenson SB. Pneumococcal type 6B conjugates differ in dependency on adjuvant and booster dose, and induce protection against type 6A as well type 6B [poster 25]. Presented at Pneumococcal Vaccines for the World 1998 conference (Washington, DC). 1998:66.
54. 54. Anttila M, Eklund C, Eskola L, Käyhty H. Functional cross-reactivity of antibodies to pneumococcal capsular polysaccharides of serotypes 6A and 6B [poster 16]. Presented at Pneumococcal Vaccines for the World 1998 conference (Washington, DC). 1998:57.
55. 55. Giebink GS, Meier JD, Quartey MK, Liebeler CL, Le CT. Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous vaccine serotypes in the chinchilla model. J Infect Dis 1996;173:119-27.